AC Immune Partners With WuXi to Speed Development of TDP-43 Antibody
AC Immune and WuXi Biologics have announced a partnership to advance the development of an investigational antibody treatment…
Articles by David Melamed, PhD
Libra Therapeutics Launches With Pipeline of 3 ALS Treatment Candidates
Libra Therapeutics has officially announced its launch with a platform dedicated to developing new treatments for neurodegenerative diseases, including …
University of Sheffield Partners With Aclipse to Advance ALS Treatment M102 to Clinical Trial
M102, a potential treatment for amyotrophic lateral sclerosis (ALS), is advancing into its first clinical study in patients…
Japan Grants Patent to Brainstorm Covering Technique for NurOwn
The Japan Patent Office has granted a patent to Brainstorm Cell Therapeutics covering the proprietary technique that generates…
PrimeC Shows Potential to Slow ALS Progression, Interim Data Reveal
PrimeC is safe and well-tolerated for the treatment of amyotrophic lateral sclerosis (ALS) and shows potential to slow…
Inhibition of RAGE Protein Lessens ALS Symptoms in Mice, Study Finds
Inhibiting the receptor for advanced glycation end products (RAGE) protein lessens the symptoms of amyotrophic lateral sclerosis (ALS), according…
Seelos to Proceed With Phase 2b/3 Trial Investigating SLS-005 for ALS
Seelos Therapeutics has received a notification from the U.S. Food and Drug Administration (FDA) permitting the launch of…
QurAlis Licenses Eli Lilly’s Preclinical Compounds That Target Neuronal Excitotoxicity
QurAlis Corporation has licensed preclinical small molecule compounds — designed to treat amyotrophic lateral sclerosis (ALS) — from…
NIH Grant Supports Work Into Cause of TDP-43 Protein Clumps in ALS, Alzheimer’s
The National Institutes of Health (NIH) has awarded a $3.3 million grant to researchers at two universities to advance studies…
Potential Stem Cell Therapy for ALS Moving into Phase 3 Trial
Seneca Biopharma announced that work is underway to advance NSI-566, its leading stem cell treatment candidate, into a Phase 3 study…